Thyroid hormone receptor (T3R) is a member of the steroid hormone receptor gene family of nuclear hormone receptors. In most cells T3R activates gene expression only in the presence of its ligand, L-triiodothyronine (T3). However, in certain cell types (e.g., GH4C1 cells) expression of T3R leads to hormone-independent constitutive activation. This activation by unliganded T3R occurs with a variety of gene promoters and appears to be independent of the binding of T3R to specific thyroid hormone response elements (TREs). Previous studies indicate that this constitutive activation results from the titration of an inhibitor of transcription. Since the tumor suppresser p53 is capable of repressing a wide variety of gene promoters, we considered the possibility that the inhibitor is p53. Evidence to support this comes from studies indicating that expression of p53 blocks T3R-mediated constitutive activation in GH4C1 cells. In contrast with hormoneindependent activation by T3R, p53 had little or no effect on T3-dependent stimulation which requires TREs. In addition, p53 mutants which oligomerize with wild-type p53 and interfere with its function also increase promoter activity. This enhancement is of similar magnitude to but is not additive with the stimulation mediated by unliganded T3R, suggesting that they target the same factor. Since p53 mutants are known to target wild-type p53 in the cell, this suggests that T3R also interacts with p53 in vivo and that endogenous levels of p53 act to suppress promoter activity. Evidence supporting both functional and physical interactions of T3R and p53 in the cell is presented. The DNA binding domain (DBD) of T3R is important in mediating constitutive activation, and the receptor DBD appears to functionally interact with the N terminus of p53 in the cell. In vitro binding studies indicate that the T3R DBD is important for interaction of T3R with p53 and that this interaction is reduced by T3. These findings are consistent with the in vivo studies indicating that p53 blocks constitutive activation but not ligand-dependent stimulation. These studies provide insight into mechanisms by which unliganded nuclear hormone receptors can modulate gene expression and may provide an explanation for the mechanism of action of the v-erbA oncoprotein, a retroviral homolog of chicken T3R␣.
Thyroid hormone (L-triiodothyronine [T3]) receptors (T3Rs) are members of a subfamily of the nuclear receptor gene family which includes the retinoic acid receptors, the retinoid X receptors, and the vitamin D receptor (20, 25, 48, 57) . Two T3R genes (T3R␣ and T3R␤ genes) have been identified in mammals (74, 95) . The T3R␣ gene in humans and rats expresses one functional receptor (T3R␣1), while the T3R␤ gene expresses two receptors (T3R␤1 and T3R␤2) which differ in their most-N-terminal regions as a result of alternative splicing (38, 48) . The chicken T3R␣ (cT3R␣) is a 408-amino-acid protein which is also the cellular homolog of the v-erbA oncoprotein of avian erythroblastosis virus (74) . Figure 1A illustrates the domains of cT3R␣, which, like other members of the nuclear receptor family, can be divided into six distinct regions (A to F) (20) . The 50-amino-acid N-terminal A/B region is the least conserved region among the nuclear hormone receptors. The highly conserved 68-amino-acid C domain (amino acids 51 to 119) is organized into two zinc finger DNA binding structures. Eighteen of the 68 residues in this DNA binding domain (DBD) are invariant and participate in the formation of the DNA-binding structure. Domains D, E, and F comprise the ligand binding domain (LBD) (amino acids 120 to 408) (40) . T3Rs bind a consensus thyroid hormone response element (TRE) half-site sequence (AGGTCA) organized as an inverted repeat (TRE-IR [also referred to as the TREp]), AGGTCA TGACCT, or a direct repeat, AGGTCANNNNAGGTCA, with a 4-bp nucleotide gap (DRϩ4) (91, 92) .
Although the binding of T3 to T3R leads to transcriptional regulation, unliganded T3R has been reported to mediate certain biologic effects. Thus, unliganded T3R, which can bind DNA without ligand, has been reported to repress or silence transcription from certain promoters containing TREs (1, 13) . This repression is thought to result from the association of transcriptional repressors with the LBD of unliganded T3R which is released as a consequence of T3 binding (8, 10, 39) . In addition to repression, we also reported that unliganded cT3R␣ or human T3R␤1 (hT3R␤1) can activate a number of promoters (29) , several of which lack TREs (36) , in specific cell types such as rat pituitary GH4C1 cells. Thus, constitutive activation by the T3Rs may be dependent on cell-specific and/ or gene-specific factors. Additional examples of constitutive activation include stimulation of a sequence in the Rous sarcoma virus (RSV) long terminal repeat (LTR) by cT3R␣ (71) , activation of the thyrotropin-releasing hormone promoter in chick hypothalamic neurons by cT3R␣ or cT3R␤ (50) , stimulation of the collagenase promoter by hT3R␤1 when c-jun is expressed (94) , and hormone-independent activation of keratin genes by cT3R␣ and hT3R␤1 (89, 90) .
The finding that constitutive activation by unliganded cT3R␣ or hT3R␤1 in GH4C1 cells (28, 29) is TRE independent and occurs with a wide variety of promoter elements (36) suggests that T3R inhibits a factor which represses promoter activity. Since the p53 tumor suppressor protein is known to strongly repress the expression of a large number of promoters lacking p53 response elements (31, 45, 73, 80) , we considered the possibility that p53 may be a candidate factor. Through this mechanism, p53 would repress promoter activity, and the interaction of cT3R␣ with p53 would then, in turn, reverse this repression.
Wild-type p53 is a tetrameric sequence-specific DNA-binding protein (43, 103) which can function as a transcriptional activator or repressor. p53 can be divided into three regions (Fig. 1B) . The N terminus (amino acids 1 to 43) contains a strong transcriptional regulatory region (21, 85, 103) . The central region (amino acids 100 to 300) contains the sequencespecific DBD (103) and four regions (II to V) that are evolutionarily conserved within all vertebrate species examined (83) . The C-terminal region contains an oligomerization domain that dictates the formation of stable p53 tetramers (amino acids 340 to 393) (84) and a nonspecific nucleic acid binding domain (amino acids 330 to 393) (93) . The majority of p53 mutations in human cancer are found in the sequence-specific DBD (Fig. 1B , regions II to V) (52) . The amino acid residues most frequently affected are at or near the protein-DNA interface (12) . Thus, these mutations may alter or destabilize the central region such that it is no longer able to interact with cognate DNA sites and modulate the transcription of gene expression (19, 44) . Heterodimerization of mutant and wildtype p53 proteins occurs through the C-terminal oligomerization region (84) , and this interaction can abrogate the activity of wild-type p53 (34, 79) .
p53 is known to interact with several viral transforming proteins (Fig. 1B) . These include simian virus 40 (SV40) T antigen (47, 53) , adenovirus E1B (101), EBNA-5 of Epstein-Barr virus (86) , and human papillomavirus type 16 E6 (97). p53 has also been shown to associate with a number of cellular proteins, such as hsp70 (64) , p34cdc2, and casein kinase II (6) and Sp1, mdm2, and components of the TFIID complex such as the TATAbinding protein (TBP) TAF II 40 and TAF II 60 (45) (Fig. 1B) .
In this study, we present evidence that endogenous levels of p53 in GH4C1 cells function to repress the activity of gene promoters. The constitutive activity mediated by T3R results from an interaction of unliganded T3R with p53, which reverses the p53-mediated repression. Similar reversal of promoter repression is also found with p53 mutants which retain the C-terminal oligomerization domain. The functional interaction of unliganded T3R with p53 involves the N terminus of p53 and the DBD of the receptor. In vitro binding studies indicate that the interaction of p53 with cT3R␣ involves the DBD of the receptor and that this interaction is partially reversed by hormone. These studies provide insight into mechanisms by which unliganded nuclear hormone receptors can modulate gene expression and may provide an explanation for the mechanism of action of the v-erbA oncoprotein.
(This study is in partial fulfillment of the requirements for Ph.D. degrees [J.-S. Qi and Y. Yuan] from the Sackler Institute for Graduate Medical Sciences at the New York University School of Medicine.)
MATERIALS AND METHODS
Cell culture and transfection. HeLa cells and GH4C1 rat pituitary cells were cultured and transfected by electroporation as previously described (1, 23, 28, 77) . Plasmids were introduced into p53-deficient SAOS-2 cells (58), into JEG-3 cells (a human choriocarcinoma cell line), or into 293T cells by calcium phos- 
7196
QI ET AL. MOL. CELL. BIOL.
phate coprecipitation (9) . The chloramphenicol acetyltransferase (CAT) reporter vectors and other plasmids used are described below. After incubation for 48 h with or without T3, cells were harvested for assay of CAT activity by a thin-layer chromatography procedure (23, 28 Plasmids. Cosx1CAT contains a 1.0-kb fragment from the first intron of the murine mdm2 gene subcloned upstream of the adenovirus major late TATA box/TdT initiation signal-CAT gene (p1634CAT) (98) and was provided by A. J. Levine. ⌬MTV-CAT contains the promoter sequence of mouse mammary tumor virus (MTV) (24, 91) . The 59-bp putative p53 response element (tGGTCAAG TTGGGACACGTCCggcgttcggctgtcggagGAGCTAAGTCCTGACATGTCT) from the first intron of the mdm2 gene (98) was cloned upstream of position Ϫ88 in ⌬MTV-CAT and is referred to as ⌬MTV-59-CAT. ⌬MTV-59(G8T)-CAT contains these 59 nucleotides with the indicated change. The pTATA-CAT and pInr-CAT plasmids each contain the SV40 early promoter 21-bp repeats and contain either the adenovirus major late promoter TATA box or the terminal transferase gene initiator element (63) , respectively, upstream of the CAT gene (55) . The proliferating cell nuclear antigen (PCNA) promoter construct pPCNA-CAT has been described previously (59) . GAL4E1BCAT has been described previously (51) , as has RSV-CAT (23) .
The full-length cT3R␣ cDNA corresponding to amino acids 1 to 408, cloned into a pEXPRESS (pEX) vector (pEX-cT3R␣), has been described previously (26) . pEX vectors contain the RSV LTR linked to a phage T7 polymerase promoter, followed by a KpnI site, stop codons in all three reading frames, and an SV40 polyadenylation signal, allowing expression in both Escherichia coli and mammalian cells and synthesis by in vitro transcription-translation with T7 polymerase and reticulocyte lysates. pEx-cT3R␣(1-118), pEx-cT3R␣(1-154), pExcT3R␣(120-408), pEx-cT3R␣(51-157), pEx-cT3R␣(1-260), pEx-cT3R␣(120-408), and pEx-cT3R␣(51-408) have been described previously (16, 32) . cT3R␣(120-408) contains the entire LBD and binds T3 with an affinity similar to that of wild-type cT3R␣ (40) . cT3R␣(1-392)VP16 was constructed from wild-type cT3R␣ in pEX by excising the DNA with SacI and AflIII, corresponding to the last 16 amino acids of cT3R␣, and replacing the DNA with the SacI-AflIII fragment from GAL4-VP16 (8) . cT3R␣(1-221)VP16 was constructed by bluntend ligation after deletion of the NaeI-SacI fragment from cT3R␣(1-392)VP16. Full-length hT3R␤1 regulated by the cytomegalovirus (CMV) promoter in a pCMX vector and a pCMX control vector (92) were kindly provided by R. Evans. pGEX2T, which expresses glutathione S-transferase (GST) in E. coli, has been described previously (82) . pGST-tat expresses a fusion protein between GST and wild-type Tat(1-86) (37, 70) . pGST-p53 and pGAL4-p53, containing human p53, were kindly provided by A. J. Berk (54) . pCMV-RB was kindly provided by W. G. Kaelin, Jr. (68) . Wild-type human p53 plasmid and the mutant human p53 plasmid p53(V143A) (provided by B. Vogelstein) utilize a pCMV-Neo-Bam vector (2) or a T7 polymerase-transcribed Bluescript vector. The human p53(59-393), p53(159-393), p53(1-326), and p53(1-376) expression plasmids (provided by S. Deb) are cloned into pCMV-Neo-Bam (85) . pEBG was kindly provided by B. Mayer. This mammalian expression vector, which is regulated by the human elongation factor 1-␣ promoter and expresses GST, has been used to express GST fusion proteins in 293T cells (87) . The entire cT3R␣(1-408) was excised from pGEX2T-cT3R␣(1-408) (32) with BamHI and was cloned into the analogous BamHI site of pEBG to form pEBG-cT3R␣ .
In vitro and in vivo cT3R␣-p53 binding assays. GST and GST fusion proteins were expressed from pGEX2T vectors in E. coli as previously described (15, 32) . The concentrations and sizes of GST or GST fusion proteins were determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis with a known quantity of molecular weight standards. L-[
35 S]methionine-labeled cT3R␣ proteins were prepared by using TNT reticulocyte lysates (Promega). Approximately 2.5 ϫ 10 4 cpm of 35 S-labeled protein was incubated with 50 to 100 ng of GST or GST fusion protein immobilized on glutathione-agarose beads in 300 l of buffer A (50 mM KCl, 25 mM HEPES [pH 7.9], 6% glycerol, 0.5 mM EDTA, 5 mM MgCl 2 , 1 mM dithiothreitol, and 0.05% Triton X-100) for 45 min at 4°C on an Orbitron rotator. Beads were collected by centrifugation at 4°C for 5 min at ϳ500 ϫ g and washed three times with 1 ml of buffer A. The bound proteins were eluted with SDS and analyzed by SDS gel electrophoresis followed by autoradiography. Where indicated, 1 M T3 was included in the binding reaction. 35 S-labeled wild-type cT3R␣ or cT3R␣ mutants were analyzed by electrophoresis and autoradiography to ensure that equal amounts of input radioactivity of all of the labeled protein were used in the GST binding assays.
Human 293T cells were transfected with pEBG or pEBG-cT3R␣(1-408) as previously described (87) . Forty hours later the cells were then harvested for the preparation of cytosol and nuclear extracts by the method of Dignam et al. (17) . Equal amounts of cell protein (about 1 mg) were incubated with glutathioneagarose for 1 h at 4°C, and the bound proteins were then analyzed for GST and p53 by Western blotting as described below.
Western immunoblotting. Assessment of the binding of purified cT3R␣ with GST or GST-p53 in vitro was similar to that in a study which examined the interaction of GST-TFIIB with purified cT3R␣ (32) . GST or GST-p53 (100 ng) was incubated with 500 ng of purified cT3R␣ with or without 1 M T3. The bound protein was eluted with SDS loading buffer and electrophoresed in an SDS-10% polyacrylamide gel. Proteins were transferred overnight to a nitrocellulose filter at 4°C in 25 mM Tris (pH 7.5)-192 mM glycine-20% methanol with a 250-mA constant current. The filter was blocked for 8 h at 4°C in TBS buffer (1 mM EDTA [pH 8 .0], 20 mM Tris [pH 7.5], 100 mM NaCl) containing 5% nonfat milk with constant agitation. The filter was then incubated in the same buffer overnight at 4°C with rabbit anti-cT3R␣ antibody no. 28 (1:1,000 dilution) (28) . After several washes with TBS buffer, the filter was incubated for 2 h at 25°C in TBS buffer containing 5% nonfat milk and 0.1 Ci of 125 I-protein A per ml. The filter was then washed several times in TBS buffer and autoradiographed. In other experiments, Western blotting by enhanced chemiluminescence (ECL) was used to determine the levels of mdm2 (monoclonal antibody 2A10) (see Fig. 5 ), GST, or human p53 (monoclonal antibody 122) (see Fig. 6 ). Electrophoresis was as described above, but the filters were blocked with buffer consisting of 10 mM Tris (pH 7.5), 150 mM NaCl, and 5% nonfat milk. Antibody 2A10 was kindly provided by A. Levine and recognizes both human and rodent mdm2. Antibody 122 was kindly provided by R. Carroll. Monoclonal antibody against GST [GST(12)] was obtained from Santa Cruz.
RESULTS
p53 inhibits the constitutive activation mediated by unliganded T3R. To explore the role of p53 in constitutive activation, GH4C1 cells were transfected with ⌬MTV-CAT, which contains no known TREs (24, 91) . This vector contains the MTV LTR deleted to position Ϫ88 linked to the CAT gene (91) . Cells were transfected with ⌬MTV-CAT alone or with vectors which express cT3R␣, p53, or the retinoblastoma (RB) gene product. After transfection, cells were incubated for 48 h in medium supplemented with hormone-depleted calf serum with or without 1 M T3 and then assayed for CAT activity (Fig. 2) . As previously found with other promoters (28, 29, 36) , cT3R␣ activated ⌬MTV-CAT in the absence of T3, and addition of T3 reversed this activation. Coexpression of p53, but not RB, inhibited constitutive activation by cT3R␣. p53 and RB are each expressed from the CMV promoter. This indicates that inhibition of cT3R␣ by p53 does not result from competition of the CMV promoter with the RSV LTR (which drives expression of cT3R␣) for a limiting transcription factor. This conclu- sion is also supported by the finding that p53 does not inhibit transcriptional activation of RSV-CAT in GH4C1 cells (data not shown). These findings suggest that p53 acts by blocking an action of unliganded cT3R␣ and not by decreasing receptor expression by the cT3R␣ expression vector.
p53 does not block T3-dependent activation by T3R. In contrast with its effect on unliganded T3R, expression of p53 did not inhibit T3-dependent activation of ⌬MTV-TREp-CAT by endogenous T3Rs in GH4C1 cells (Fig. 3 ). This suggests that p53 blocks constitutive activity mediated by unliganded T3R but not activation by ligand-bound T3R. This conclusion is supported by studies with HeLa cells, which contain low levels of p53 (76) and exhibit ligand-dependent but not ligand-independent activation by cT3R␣ (1, 8, 24, 77) (Table 1) . Expression of cT3R␣ in HeLa cells resulted in marked T3-dependent stimulation of ⌬MTV-TREp-CAT. This stimulation was only marginally affected by expression of p53 at levels which maximally activate ⌬MTV-59-CAT, which contains a 59-bp p53 response element from the first intron of the mdm2 gene (98) cloned at position Ϫ88 of ⌬MTV-CAT (Table 1) . p53 did not stimulate expression of ⌬MTV-CAT or ⌬MTV-59(G8T)-CAT, which contains the indicated mutation in the p53 response element (data not shown).
Reversal of p53-mediated repression of TATA-and initiator-mediated transcription by cT3R␣ in GH4C1 cells. Transfection of GH4C1 cells with Cosx1CAT or ⌬MTV-59-CAT indicates that these cells contain functional p53 (Fig. 4 ). Cosx1CAT contains a p53-responsive intronic sequence from the mdm2 gene cloned into p1634CAT (98) . Unlike with HeLa cells, which contain low levels of p53, high levels of CAT expression were found in GH4C1 cells with ⌬MTV-59-CAT and Cosx1CAT (Fig. 4) . In contrast, low activity was observed with p1634CAT (the base vector for Cosx1CAT), ⌬MTV-CAT, or ⌬MTV-59(G8T)-CAT. Further evidence that GH4C1 cells contain p53 with wild-type activity comes from studies indicating that these cells express high levels of mdm2 (Fig. 5) , which is known to be transcriptionally stimulated by p53 (5, 41, 98) .
Cotransfection of a wild-type human p53 expression vector with various reporter genes, including pSV2-CAT, p56fosCAT, and pTATA-CAT (55), has been reported to result in a dosedependent repression of transcription. Repression of pInr-CAT by p53 appears to be cell type dependent, since repression has been reported to occur in HeLa cells (72) but not in C33A cells, another human cervical cell line (55). Mack et al. (55) also reported that the PCNA promoter is resistant to the repressive effect of p53 in C33A cells. We used several of these reporter genes to further study the role of endogenous p53 in the cT3R␣-mediated constitutive activation (Table 2) . pTATA-CAT and pInr-CAT contain SV40 21-bp repeats and either the adenovirus major late promoter TATA box or the terminal transferase gene initiator element, respectively, upstream of the CAT gene (55) . Table 2 shows that the basal expression of pTATA-CAT was very low in GH4C1 cells and that expression 
a HeLa cells were transfected by electroporation with 10 g of ⌬MTV-TREp-CAT alone or with expression vectors for cT3R␣ (1 g) and p53 (2, 4, or 8 g) as indicated. One transfection was performed with a CMV promoter control vector, which is the vector used to express p53. To establish that p53 was expressed, HeLa cells were transfected with ⌬MTV-59-CAT alone (10 g) or with the expression vector for p53 (2, 4, or 8 g). ⌬MTV-59-CAT contains a 59-bp p53 response element from the mouse mdm2 gene. Cells were incubated for 48 h with or without 500 nM T3 as indicated and then harvested for determination of CAT activity. Results are from a representative experiment of three independent transfections. of cT3R␣ activated the reporter and T3 reversed this activation. Similar results were observed with pInr-CAT, except that it showed higher basal levels of activity in GH4C1 cells. In contrast, pPCNA-CAT, which is not repressed by p53 (55), was highly active in GH4C1 cells, and expression of cT3R␣ did not affect its activity (Table 2) .
p53 mutants and cT3R␣ target the same inhibitory factor in GH4C1 cells. The results in Table 2 indicate that constitutive activation by cT3R␣ in GH4C1 cells involves promoters that are inhibited by p53, suggesting that cT3R␣ acts by reversing p53-mediated repression. Further evidence to support this notion is provided by dominant negative p53 mutants. Certain p53 mutants, found in human tumors, have been reported to block the activity of wild-type p53 (44) by mechanisms which are thought to involve heterodimerization of mutant and wildtype p53 (34, 79, 84) . Differences in activation by wild-type human p53 and several p53 mutants were determined by transient-transfection studies with GH4C1 cells (Table 3) . Cells were transfected with ⌬MTV-CAT alone or with expression vectors for wild-type cT3R␣, cT3R(120-408), wild-type p53, or the dominant negative p53(V143A) mutant (Table 3 , experiment 1). Transcriptional activity was only slightly elevated when 5 g of the p53(V143A) expression vector was transfected into GH4C1 cells but increased to ϳ70-fold when 20 g of the same vector was used. Similarly, the reporter was only slightly activated when 5 g of cT3R␣ expression vector was used, and this activation increased to ϳ50-fold with 20 g of the vector. These results suggest that both cT3R␣ and p53 (V143A) attain a threshold level where they titrate a factor which represses promoter activity. p53(V143A) accelerates tumor development in heterozygous but not nullizygous p53-deficient mice, suggesting that the mutant acts as a dominant negative modulator of wild-type p53 (34) . Thus, our finding of activation by p53(V143A) is consistent with a mechanism where ⌬MTV-CAT is normally repressed by wild-type p53. p53(V143A) activates by reversing this repression, most likely by the formation of p53(V143A)-wild-type p53 oligomers, which do not allow for repression. Consistent with this notion is the finding that p53(59-393) and p53(159-393) activate ⌬MTV-CAT similarly to p53(V143A) ( Table 3 , experiment 2). The N terminus of p53 is involved in activation and repression (85) , and the C terminus (amino acids 340 to 393) is involved in oligomerization (84, 85, 93) . Thus, p53(59-393) or p53(159-393) would not be expected to activate or repress but could oligomerize with wild-type endogenous p53 and, thus, reverse p53-mediated inhibition. The similar levels of activation of ⌬MTV-CAT by cT3R␣ and the p53 mutants suggest that they each target p53 to reverse p53-mediated repression. This conclusion is also supported by the finding that coexpression of cT3R␣ with the p53 mutants does not lead to even greater activation but results in levels of activation similar to those seen with the p53 mutants or cT3R␣ alone (Table 3 , experiment 2). JEG-3 cells, a human chorio- (46), showed similar responses to expression of cT3R␣ and the p53 mutants as did GH4C1 cells (Table 4 ). Our conclusion that p53(V143A) functions in GH4C1 and JEG-3 cells via its ability to act as a dominant negative inhibitor of p53, however, should be considered tentative, since Dittmer et al. (18) reported that p53 (V143A) acted as a gain-of-function mutant in p53-deficient mouse (10)3 cells, although it was inactive in p53-deficient SAOS-2 cells. The N terminus of p53 is required for inhibition of constitutive activation by cT3R␣. The results in Tables 3 and 4 with p53(59-393) or p53(159-393) suggest that the N terminus of p53 is important for mediating repression by p53, and this is consistent with previous studies with other cell types (85) . To further study this repression, we transfected GH4C1 cells with p53(1-326) and p53(1-376) ( Table 3 , experiment 2). These mutants contain the N terminus of p53 but lack the C-terminal oligomerization domain. As predicted, neither of these p53 mutants activated ⌬MTV-CAT. However, p53(1-326) and p53 (1-376) each prevented constitutive activation by cT3R␣ in a fashion similar to that for wild-type p53 ( Fig. 2 and Table 3 ). These mutants provide further evidence for involvement of the C-terminal oligomerization domain in reversing effects of wildtype p53. In addition, the results with p53(1-326) and p53 (1-376) also indicate that inhibition of constitutive activation by cT3R␣ requires the N terminus and not the C-terminal region of p53 in GH4C1 cells.
Evidence for physical interaction of T3R with p53 in vivo. Several approaches were used to identify an interaction between T3R and p53 in the cell. Immunoprecipitations of cell lysates with various anti-cT3R␣ antibodies were not revealing. However, we found that various anti-cT3R␣ antibodies did not immunoprecipitate cT3R␣-p53 complexes in vitro. In addition, these antibodies blocked the interaction of 35 S-cT3R␣ with GST-p53 in vitro (see Fig. 11 ), suggesting that p53 interferes with antibody recognition of the complex. Thus, we used pEBG-cT3R␣(1-408), a mammalian GST-cT3R␣(1-408) expression vector, to determine if p53 could interact with receptor in vivo. 293T cells were used in these studies, since the promoter in the pEBG vector has been shown to express GST fusion proteins in these cells (87) . In transfection studies, GSTcT3R␣(1-408) was found to be as active as wild-type cT3R␣ (1-408) in mediating basal repression and ligand-dependent activation of ⌬MTV-TREp-CAT. For analysis of in vivo p53 interactions, cells were transfected with pEBG-cT3R␣(1-408) or the pEBG GST control vector. Forty hours later the cells were harvested, and the cytosol and nuclear fractions were prepared by the method of Dignam et al. (17) . Nuclear extracts and cytosol were incubated with glutathione-agarose for 1 h at 4°C. The beads were then washed, boiled in SDS loading buffer, and then analyzed for GST or p53 by Western blotting. Figure 6A shows that nuclear extracts contain similar amounts of GST or GST-cT3R␣(1-408) following transfection with the indicated pEBG vectors. However, immunoreactive p53 was detected only in the nuclear extracts of cells expressing GSTcT3R␣(1-408) (Fig. 6B) . Although immunoreactive GST was also present in the cytosolic fraction, GST-cT3R␣(1-408) was not detected, and no p53 was identified in the assay (not shown).
Additional evidence for an in vivo T3R-p53 interaction is provided by studies indicating that T3R can increase the cellular level of p53, presumably by a mechanism which involves p53 stabilization. The half-life of wild-type p53 in the cell is relatively short (about 15 to 30 min) (62, 69) . Thus, certain proteins which interact with p53 in vivo, such as the Wilms' tumor protein (WT1), decrease the rate of p53 degradation and increase the level of p53 as determined by Western blotting (56) . To provide further evidence that T3R can interact with p53 in vivo, we compared the effects of WT1 and T3R on p53 levels when these proteins were coexpressed in SAOS-2 cells (Fig. 7) . hT3R␤1 was used instead of cT3R␣ in this study since either form of T3R mediates constitutive activation in GH4C1 cells (28, 29) . In addition, hT3R␤1 was constructed in a CMV expression vector (92) similar to that for WT1 and p53 (56), which we found to express efficiently in SAOS-2 cells. The level of expressed p53 was not altered by cotransfection with the control CMV vector (Fig. 7) . As previously reported, coexpression of p53 with WT1 resulted in an increase in p53 levels (56) . Coexpression of p53 and hT3R␤1 resulted in an increase in p53 levels similar to that found with WT1 (Fig. 7) , further supporting the notion that T3R and p53 can interact in vivo.
Functional interaction of p53 with cT3R␣ in HeLa cells. Additional evidence for an in vivo interaction between cT3R␣ and p53 comes from studies using a two-hybrid-like system in mammalian cells (Fig. 8) . We (66) and others (27) have used this approach to document that protein-protein interactions between T3R and RXR occur in vivo independent of DNA binding (66) . HeLa cells, which lack endogenous T3Rs (77) and are deficient in p53 (76) , were cotransfected with a GAL4 reporter, G4E1BCAT, along with an expression vector for GAL4-p53 alone or with two T3R-VP16 chimeras. cT3R␣(1-392)VP16 is a chimera which has the potent 90-amino-acid activating region of the herpes simplex virus VP16 protein replacing the last 16 amino acids of cT3R␣. This chimera has low affinity for T3 (8) . The second chimera, cT3R␣(1-221) VP16, links amino acids 1 to 221 of cT3R␣ to the activation domain of VP16. Figure 8 shows that GAL4-p53 weakly activates G4E1B-CAT in HeLa cells. However, coexpression of cT3R␣(1-221)VP16 and GAL4-p53 resulted in enhanced (ϳ10-fold) activation of the reporter. In contrast, coexpression of GAL4-p53 and cT3R␣(1-392)VP16 did not increase the activity of GAL4-p53. However, coexpression with cT3R␣(120-408), which is inactive when expressed alone (Table 3 , experiment 1) (8, 28, 77) , resulted in an ϳ35-fold activation of the reporter (Fig. 8) . This finding is consistent with previous studies from our laboratory (8, 66) and others (4, 10, 39) indicating that a transcriptional inhibitory factor(s) reversibly binds to the LBD of the T3Rs. Thus, activation by cT3R␣(120-408) is consistent with a model in which GAL4-p53 associates with the N-terminal region of cT3R␣(1-392)VP16, which is inactive as a result of the association of its LBD with an inhibitory factor. Titration of the inhibitory factor by cT3R␣(120-408) leads to transcriptional activation by cT3R␣(1-392)VP16, which remains bound to GAL4-p53 via its N-terminal region. Consistent with this conclusion is the finding that cT3R␣(1-221) VP16, which lacks most of the LBD, does not require coexpression of cT3R␣(120-408) for activation when expressed with GAL4-p53.
The DBD of cT3R␣ is essential for the p53-cT3R␣ interaction. The results in Fig. 8 suggest that the region of cT3R␣ which is N terminal (amino acids 1 to 221) to the LBD is involved in the interaction of cT3R␣ with p53 in the cell. To further define the N-terminal region of cT3R␣ that mediates constitutive activation, GH4C1 cells were transfected with ⌬MTV-CAT alone or with vectors expressing various deletion mutants of cT3R␣ (Fig. 9) . Expression of cT3R␣(1-118), cT3R␣(51-157), or cT3R␣(1-260), but not cT3R␣(120-408), resulted in constitutive activation of ⌬MTV-CAT, indicating that the DBD (amino acids 51 to 118) of the receptor is necessary for this activity.
Binding assays with GST fusion proteins were used to define the region(s) of cT3R␣ which physically interacts with p53 in vitro (Fig. 10) . GST protein alone bound poorly to 35 S-labeled wild-type cT3R␣(1-408) (Fig. 10A) . As previously reported (15) , cT3R␣ interacts with human immunodeficiency virus type 1 (HIV-1) Tat when linked to GST, and T3 does not affect the binding of GST-tat to cT3R␣. We have previously shown that HIV-1 tat, a potent activator that is essential for gene expression and replication of HIV-1 (14, 22) , both functionally and physically interacts with T3R (15, 16) . In contrast, 35 S-labeled cT3R␣ bound to GST-p53, and T3 reduced the amount of cT3R␣ which bound to GST-p53 (Fig. 10B) . S-labeled wild-type and mutant cT3R␣s and GSTp53, we delineated the regions of cT3R␣ essential for the interaction with p53 (Fig. 10B) . GST protein alone bound poorly to 35 S-labeled wild-type cT3R␣(1-408). In contrast, GST-p53 bound wild-type cT3R␣(1-408) with an affinity similar to those of cT3R␣ mutants containing only the A/B/C domains [cT3R␣ (1-118)] or the A/B/C domains plus part of the D domain [cT3R␣ (1-154) ]. However, cT3R␣(120-408), containing the LBD, bound poorly to GST-p53. Other binding studies (Fig.  10C) indicate that p53 interacts primarily with sequences within amino acids 51 to 157 of the receptor. Taken together, these findings indicate that p53 interacts primarily with the sequences within the DBD (C region) (amino acids 51 to 118) of cT3R␣. The physical interaction between cT3R␣ and GSTp53 and the effect of T3 were also confirmed by Western immunoblot analysis with E. coli-expressed and -purified cT3R␣ (Fig. 11) .
DISCUSSION
Constitutive activation of gene expression by T3R. Liganddependent activation of gene expression by T3R results from a T3-mediated conformational change of the LBD of DNAbound receptor. This conformational change is thought to release an inhibitory factor(s) that is bound to the LBD of unliganded T3R, which acts to represses transcription (4, 8, 10, 39) . In addition, this conformational change may also recruit coactivator proteins to the receptor which serve to link structural changes in the LBD to the transcriptional apparatus (49, 61) . Although most known effects of T3R are ligand dependent, hormone-independent or constitutive activation by T3Rs has been described for a number of promoter elements and for several cell types (28, 29, 36, 50, 71) . The first example of constitutive activation by the T3Rs was in GH4C1 cells, where expression of hT3R␤1 or cT3R␣ was found to activate the promoters of the rat growth hormone and prolactin genes (29) .
Several lines of evidence indicate that constitutive activation in GH4C1 cells involves mechanisms which differ from liganddependent activation. First, deletion of the last 16 amino acids of cT3R␣, which is essential for T3-dependent stimulation, does not alter the extent of constitutive activation (28) . Second, T3 appears to reverse the extent of constitutive activation rather than to further potentiate gene transcription ( Fig. 2 and Table 2 ) (29, 36) . Third, hormone-independent activation in GH4C1 cells occurs with a variety of gene promoters and does not appear to require a known TRE (Tables 2 and 3 ) (36). Constitutive activation is not restricted to GH4C1 cells but also occurs in JEG-3 cells (Table 4) , in U937 cells (75) , and in hypothalamic neurons (50) . Expression of T3Rs in many cell types leads to gene silencing, which is thought to be mediated by cellular inhibitors or corepressors which bind to the LBD of DNA-bound unliganded T3Rs (4, 8, 10, 39) . In contrast, expression of T3Rs in GH4C1 cells does not lead to silencing but only to hormone-independent activation. GH4C1 cells appear to have low levels of functional corepressor(s) (8) , which may explain why expression of unliganded T3R leads to constitutive activation in GH4C1 cells rather than to gene silencing. Hormone-independent or constitutive activation by T3Rs FIG. 10 . p53 interacts with the DBD of cT3R␣ in vitro. GST-p53 was expressed in E. coli and purified by immobilization on glutathione-agarose beads. GST (negative control) and GST-tat (positive control) were also expressed and purified. cDNAs for wild-type cT3R␣(1-408) and its mutants were transcribed and translated in vitro with T7 phage RNA polymerase in rabbit reticulocyte lysates in the presence of L-[
35 S]cysteine. A control lysate containing no plasmid DNA was also radiolabeled. The labeled proteins with or without 1 M T3 were incubated at 4°C for 45 min with 100 ng of GST or GST fusion proteins immobilized on glutathione-agarose beads. After several washes, bound proteins were eluted, electrophoresed in SDS gels, and autoradiographed. FIG. 11 . T3 reduces the affinity of purified cT3R␣ for p53. Bacterially expressed and purified cT3R␣ (23) was incubated with GST (lane 1) or with GST-p53 glutathione-agarose beads in either the absence (lanes 1 and 2) or presence (lane 3) of 1 M T3. After washing, the bound proteins were eluted, separated by SDS gel electrophoresis, and transferred to nitrocellulose membranes. The membranes were incubated with rabbit anti-cT3R␣ antibody (28, 32) , probed with 125 I-labeled protein A, and visualized by autoradiography.
in GH4C1 cells may result from a positive action of T3R on the transcriptional apparatus or from an effect of T3R to inactivate a factor(s) that represses transcription. We present results in this study which support the latter model and the idea that unliganded T3R acts to reverse p53-mediated repression of gene activity. Endogenous p53 mediates repression of promoter activity in GH4C1 cells. p53 is a sequence-specific DNA-binding protein (43, 103) which can activate transcription of several native promoters (5, 42, 96, 98, 103) . Target genes activated by p53 contain p53 binding sites which conform to the 10-bp motif 5Ј PuPuPuC(A/T)(A/Y)GPyPyPy 3Ј. Paradoxically, p53 can repress the transcription in vivo of a number of genes that have no apparent p53 binding sites (31, 73, 80) . The mechanism(s) by which p53 mediates this repression has yet to be established (45) and may be direct and/or indirect via regulation of one or more gene products by p53. However, wild-type p53 has been shown to act both in vivo and in vitro to repress the activity of promoters where initiation is dependent on the presence of a TATA box or, depending on the cell type, an initiator element (55, 72) .
Since studies on repression by p53 involve transfection to express wild-type p53 in cells, the biological consequences and functional significance of repression in vivo by endogenous p53 are not fully established. However, several observations suggest that repression might be a physiologically relevant activity of p53. First, wild-type p53 inhibits transcription, while a variety of p53 mutants do not repress (31, 80) , correlating repression with normal function of the protein. Second, repression exhibits promoter specificity in that not all promoters lacking p53 response elements are inhibited in transfection assays (31, 55) . Third, recent reports have demonstrated that induction of wild-type p53 specifically represses several endogenous cellular genes that regulate cellular proliferation and apoptosis (e.g., c-myc [51, 102] and the cyclin A gene [78, 99] ), although the mechanism of the repression is not yet established.
Our study extends these previous findings and demonstrates that endogenous levels of p53 in GH4C1 cells are involved in the repression of several promoters linked to reporter genes (⌬MTV-CAT, pTATA-CAT, and pInr-CAT) (Tables 2 and 3 ). In addition, endogenous p53 and transiently expressed p53 in GH4C1 cells do not inhibit the expression of pPCNA-CAT (Table 2 ). This is in agreement with a previous study of pPCNA-CAT in other cell lines (55) . The notion that endogenous p53 mediates repression in GH4C1 cells is also supported by the finding that expression of p53(V143A), p53(59-393), or p53(159-393), which are thought to heterodimerize with and inactivate endogenous wild-type p53, leads to activation (Table 3) . Our observation that certain threshold levels of expression are necessary for activation by p53 mutants (Table  3 ) also supports this conclusion.
Constitutive activation of gene expression by T3R results from reversal of p53-mediated repression. T3R constitutively activates many gene promoters in GH4C1 cells that contain no known TREs (36) . Based on this finding, we considered the possibility that this effect of unliganded T3R is mediated by the inactivation of a repressor of the basal transcriptional apparatus. Several lines of evidence indicate that this transcriptional repressor in GH4C1 cells is p53. First, p53 blocks constitutive activation mediated by cT3R␣ ( Fig. 2 and Table 3 ). Second, the extent of activation by cT3R␣ is similar to that found with p53(V143A), p53(59-393), or p53(159-393) (Table 3) . Third, the effect of T3R and the p53 mutants is not additive ( Table 3 ), suggesting that T3R and the p53 mutants target the same factor in the cell. Since the p53 mutants are thought to act by forming inactive oligomers with wild-type p53 (34, 79, 84) , this suggests that the constitutive effect of T3R is also mediated through reversal of p53-mediated repression. This conclusion is also supported by the finding that the PCNA promoter is not constitutively activated by cT3R␣ (Table 2 ) and is one of the promoters that is not repressed by p53 (55) . Additional evidence for an in vivo T3R-p53 interaction comes from studies indicating that cT3R-VP16 chimeras can lead to enhanced activation of a GAL4 reporter when coexpressed with GAL4-p53 (Fig. 8) . Furthermore, the Western blotting studies shown in Fig. 6 and 7 also indicate that T3R can interact with p53 in vivo.
Although our results indicate that T3R can interact with p53 in SAOS-2 cells (Fig. 7) , we were not able to document that expression of cT3R␣ or hT3R␤1 could reverse repression mediated by expressed p53 in SAOS-2 cells. First, the reporter genes used in our studies (⌬MTV-CAT, pTATA-CAT, and pInr-CAT) exhibited very low levels of expression, which precluded a study of p53-mediated repression and its reversal by T3R (data not shown). However, using pSV2-CAT and CMV-CAT, we found that expression of p53 led to repression of CAT activity and that cT3R␣ resulted in only a partial reversal of p53-mediated inhibition. Similar results were found for 10(1) cells, a murine p53 null fibroblast line (98) . Although the reason for the difference in the T3R-mediated responses found with GH4C1 and JEG-3 cells and with the p53-null SAOS-2 and 10(1) cells is unclear, it may reflect differences in the p53 response of these cell lines, since cellular responses to p53 (e.g., apoptosis or inhibition of cell growth) are known to be cell type dependent (35, 88) . It is also interesting that the two cell lines in which constitutive activation by T3R was found to occur (GH4C1 and JEG-3) express high levels of mdm2. The significance of this finding is unclear, but it may reflect an inherent property of these cells to respond to p53 due to postsynthetic modification or that p53 regulates one or more genes that cooperate with p53 in mediating repression.
The p53-T3R interaction in vivo and in vitro requires the T3R DBD. Transfection studies indicate that the LBD is not required for constitutive activation and that this effect is mediated by expression of cT3R␣(1-118), cT3R␣(1-154), or cT3R␣(51-157), all of which contain the DBD (amino acids 51 to 118) of the receptor (Fig. 9) . Although cT3R␣(1-118) contains the DBD, the protein exhibits a very low affinity for TREs because it lacks the basic amino acid sequence C terminal to the DBD (amino acids 119 to 154) which is involved in DNA binding (30) . Thus, the finding that cT3R␣(1-118) mediates constitutive activity suggests that binding of the receptor to DNA is not required for constitutive activity, and this is consistent with the observation that this effect occurs with promoters that do not contain known TREs (36) .
GST-p53 binding assays indicate that cT3R␣ proteins which contain the DBD [cT3R␣(1-408), cT3R␣(1-118), cT3R␣(1-154), and cT3R␣(51-157)] bind to p53, while the LBD [cT3R␣(120-408)] does not (Fig. 10) . These findings along with functional studies (Fig. 9) identify the DBD of T3R as a domain for protein-protein interactions. Other studies which point to the DBD of transcription factors as an interface for protein-protein interactions include the interaction of the DBD of Sp1 with human TAF II 55, adenovirus E1A, or YYI (11) and the interaction of the T3R DBD with TLS (65) or with the HIV-1 transactivator Tat (15) . In contrast with p53 (see below), T3 does not decrease the interaction of T3R with Tat, and Tat does not alter the binding of T3R to DNA (15) . Although we have not identified the region(s) of p53 that interacts with T3R by in vitro binding studies, functional studies indicate that the N-terminal region of p53 is required for the interaction (Table  3) . This is the same region of p53 that is thought to interact with mdm2, TFIID, TBP, TAF40, TAF60, TFIIH, and adenovirus E1B (Fig. 1) (45) . If repression by p53 was mediated through the interaction of the N terminus of p53 with one of the TFIID components, constitutive activation by T3R could result from blocking the interaction of p53 with these factors.
Ligand reverses the functional interaction of T3R with p53. Although both functional and physical evidence indicates that p53 interacts with the DBD of T3R in the absence of ligand ( Fig. 9 and 10) , our results also indicate that ligand can decrease the T3R-p53 interaction. First, GST-p53 binding studies indicate that T3 decreases the binding of reticulocyte lysatesynthesized cT3R␣ as well as purified cT3R␣ to p53 (Fig. 10  and 11) . Second, constitutive activation by cT3R␣ in GH4C1 cells, which appears to be mediated by reversal of p53-mediated repression, is reduced by T3 (Fig. 2 and Table 2 ). Last, functional studies indicate that expression of p53 does not significantly inhibit ligand-dependent stimulation by cT3R␣ in HeLa cells (Table 1) or by endogenous T3Rs in GH4C1 cells (Fig. 3) . While this work was in progress (67), Yap et al. (100) reported that hT3R␤1 could bind GST-p53 and several GSTp53 mutants (175H or 273H) through its DBD. In addition, wild-type p53 and the p53 mutants blocked the binding of hT3R␤1 as homodimers or as a heterodimer with mRXR␤ to several TREs (100). In contrast with our findings (Fig. 3 and Table 1 ), expression of wild-type p53 was reported to block T3-dependent activation of reporter genes containing TREs in CV-1 cells as well as HeLa cells (100) . Since the p53 mutants did not block T3-mediated stimulation but did inhibit the binding of hT3R␤1 to the TREs in vitro (100), the mechanism of inhibition of T3 stimulation by wild-type p53 was unclear (100). The reason for the differences in the effects of wild-type p53 on T3-dependent stimulation by T3R in our study and that of Yap et al. (100) is unknown. Both studies used a similar wild-type p53 expression vector (44) , although the mode of transfection differed: electroporation (66) versus lipofection (100), which may give much higher levels of expression. However, additional support for the conclusion that p53 does not block T3-dependent stimulation comes from studies with GH4C1 cells indicating that expression of wild-type p53 does not inhibit ligand-dependent activation by endogenous rat T3Rs (T3R␣1, T3R␤1, and T3R␤2) (Fig. 3) .
Mechanism of hormone-independent activation by T3R and its biological implications. Our findings suggest the following model to explain the activation of a number of promoters by unliganded T3R and mutant p53s in GH4C1 cells (Fig. 12) . Endogenous p53, possibly through interaction with another factor(s), represses promoter activity. Overexpression of p53 (V143A), p53(59-393), p53(159-393), cT3R␣, or cT3R␣ fragments containing the DBD (amino acids 51 to 118) interacts with wild-type p53 and reverses its ability to repress promoter activity. A defined TRE is not required for this activation, since constitutive activation by cT3R␣ or hT3R␤1 (29) occurs with promoters that do not contain a known stimulatory TRE (36) . Furthermore, constitutive activation occurs with cT3R␣(1-118) (Fig. 9) , which inefficiently binds DNA. Finally, T3 reverses constitutive activation mediated by wild-type T3R, possibly by decreasing the interaction of p53 and T3R ( Fig. 10 and 11) .
Constitutive activation by T3R contrasts with the repression or silencing of gene expression which occurs in the absence of hormone in a number of cell lines (1, 3, 7, 13) . Whether unliganded T3R acts as a constitutive activator to relieve the repression by wild-type p53 or as a silencer of gene activation in the organism is not yet known. Since this effect of T3R on p53 activity appears to involve elevated expression of receptor, our findings may provide an explanation of the mechanism of action of the v-erbA oncoprotein. v-erbA is an avian retroviral counterpart of cT3R␣ (74) , which differs from cT3R␣ by two amino acids in the DBD, nine amino acids in the v-erbA region corresponding to the LBD, and a nine-amino-acid deletion near its most C terminus (74, 77) . As a result of these changes, v-erbA binds T3 with relatively low affinity (40, 60) and exhibits minor changes in DNA response element recognition (81). Although we have found that v-erbA expressed from the RSV LTR is a much less efficient constitutive activator in GH4C1 cells than cT3R␣ (36) , v-erbA is expressed at extremely high levels after the infection by avian erythroblastosis virus. A retroviral vector in which the LBD region of v-erbA was replaced with the analogous region of cT3R␣ [v-erbA/cT3R␣ (LBD)] also mediates transformation (104) . However, unlike the case for v-erbA, the effect of the v-erbA/cT3R␣(LBD) chimera is reversed by T3. The reversal of the transformation potential of the v-erbA/cT3R␣(LBD) chimera by T3 is reminiscent of the T3 reversal of constitutive activation by cT3R␣ in GH4C1 cells (Fig. 2) . These observations, along with our studies on the interaction of cT3R␣ with p53, raise the possibility that v-erbA may act to transform cells by binding to and functionally inhibiting the action of wild-type p53.
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